Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 10/20 | 0.38 |
| ▸ | IDH2 | P48735 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391766 | 0.90 | IDH1 (0.46) | TGFBR1KMT2ACA2CHKAKDM4E | |
| SCHEMBL17812911 | 0.88 | IDH1 (0.48) | TGFBR1KMT2ATHRBKDM4ECYP1A2 | |
| SCHEMBL17812910 | 0.86 | CYP1A2 (0.55) | TGFBR1KMT2ATHRBKDM4ECYP1A2 | |
| SCHEMBL17812918 | 0.83 | TGFBR1 (0.54) | TGFBR1KMT2AIDH1IDH2 | |
| SCHEMBL17812906 | 0.83 | SYK (0.50) | TGFBR1THRBIDH2 | |
| SCHEMBL17812907 | 0.82 | IDH1 (0.40) | TGFBR1KMT2ATHRBKDM4ECYP1A2 | |
| SCHEMBL17812912 | 0.79 | PTGS2 (0.49) | — | |
| SCHEMBL16392177 | 0.78 | IDH1 (0.58) | KMT2AKDM4EIDH1IDH2 | |
| SCHEMBL16392057 | 0.76 | IDH1 (0.57) | CYP1A2IDH1IDH2 | |
| SCHEMBL16392099 | 0.75 | SYK (0.46) | KMT2AIDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | TGFBR1 3893/4885KMT2A 329/4885THRB 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.